oxazoles has been researched along with rifampin in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 8 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Papezhova, E; Toushek, I | 1 |
| Urbanczik, R | 1 |
| Rao, M; Rattan, A; Singhal, S; Sood, R | 1 |
| Haraguchi, Y; Hashizume, H; Itotani, M; Kawasaki, M; Komatsu, M; Kuroda, H; Matsumoto, M; Sasaki, H; Tomishige, T; Tsubouchi, H | 1 |
| Zhang, Y | 1 |
| Schaberg, T | 1 |
| Centárová, I; Cole, ST; Čonka, P; Hrabálek, A; Karabanovich, G; Klimešová, V; Mikušová, K; Němeček, J; Pávek, P; Pávková, I; Roh, J; Šarkan, M; Smutný, T; Stolaříková, J; Székely, R; Vávrová, K; Vejsová, M; Vocat, A; Zemanová, J | 1 |
| Geiter, L; Mallikaarjun, S; Paccaly, A; Patil, S; Petersen, C; Shoaf, SE; Wells, C | 1 |
| Greenwood-Quaintance, KE; Mandrekar, J; Park, KH; Patel, R | 1 |
| Cox, V; Furin, J; Lessem, E | 1 |
| Falzon, D; Halleux, CM; Jaramillo, E; Merle, C; Mirzayev, F; Olliaro, P; Weyer, K | 1 |
| Alvarez, DN; Bayer, AS; Farah, S; Garcia-de-la-Maria, C; Miro, JM; Mishra, NN; Sakoulas, G; Zapata, B | 1 |
| Ade, S; Alikhanova, N; Benedetti, G; Cox, H; Daniels, J; De Azevedo, V; Edwards, J; Ferlazzo, G; Furin, J; Hughes, J; Isaakidis, P; Kock, Y; Mohr, E; Reuter, A; Shroufi, A; Steele, SJ; Trivino Duran, L | 1 |
| Flexner, C; Moss, DM; Owen, A; Podany, AT; Rajoli, RKR; Siccardi, M; Swindells, S | 1 |
| Balanag, V; Bielskiene, V; Cadena, E; Caoili, J; Cirule, A; Danilovits, M; Davidaviciene, E; Domente, L; Geiter, LJ; Gupta, R; Hafkin, J; Hittel, N; Lizarbe, V; Patientia, R; Petersen, C; Sanchez, E; Segura, P; Staples, S; Ticona, E; Variava, E; von Groote-Bidlingmaier, F; Wells, C; Yu, C | 1 |
| Alós-Almiñana, M; Ezquer-Garin, C; Ferriols-Lisart, R; Martinez-López, LM; Nicolás-Picó, J; Sangrador-Pelluz, C | 1 |
| Beko, B; Cox, H; Daniels, J; De Avezedo, V; Ferlazzo, G; Furin, J; Hughes, J; Isaakidis, P; Kock, Y; Makhanda, G; Mohr-Holland, E; Reuter, A; Trivino Duran, L | 1 |
| Ampaw, L; Beysen, C; Garrison, KL; Kearney, BP; Kirby, BJ; Lutz, JD; Mathias, A; Myers, RP; Qin, AR; Yue, MS | 1 |
| Comins, K; Conradie, F; Cramer, YS; De Los Rios, J; Diacon, AH; Donahue, K; Dooley, KE; Hafner, R; Lama, JR; Maartens, G; Moran, L; Morganroth, J; Rosenkranz, SL; Shenje, J; von Groote-Bidlingmaier, F | 1 |
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
| Ahmed, S; Bastard, M; Franke, MF; Grium Tefera, D; Hewison, C; Holtzman, D; Huerga, H; Islam, S; Jacques Leblanc, G; Khan, PY; Khan, U; Kumsa, A; Lachenal, N; Leonovich, O; Mamsa, S; Manzur-Ul-Alam, M; Melikyan, N; Mitnick, CD; Myint, Z; Osso, E; Padayachee, S; Rafi Siddiqui, M; Rashitov, M; Rich, ML; Salahuddin, N; Salia, G; Sánchez, E; Serobyan, A; Seung, KJ; Varaine, F; Vetushko, D; Yeghiazaryan, L | 1 |
| Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L | 1 |
| Apolisi, I; Beko, B; Cengani, L; Cox, H; Daniels, J; Fatshe, S; Furin, J; Gumede, N; Joseph, K; Mathee, S; Maugans, C; Memani, B; Reuter, A; Tyeku, N | 1 |
3 review(s) available for oxazoles and rifampin
| Article | Year |
|---|---|
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
[Tuberculosis: new treatment options and updated recommendations].
Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2013 |
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |
4 trial(s) available for oxazoles and rifampin
| Article | Year |
|---|---|
Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Ethambutol; Female; Healthy Volunteers; Humans; Isoniazid; Male; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2016 |
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
Topics: Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Oxazoles; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat.
Topics: Adult; Drug Interactions; Female; Humans; Isobutyrates; Liver; Male; Middle Aged; Organic Anion Transporters; Oxazoles; Pyrimidines; Rifampin | 2021 |
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Nitroimidazoles; Oxazoles; Peru; Rifampin; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
16 other study(ies) available for oxazoles and rifampin
| Article | Year |
|---|---|
[Remote results of chemotherapy in tuberculosis].
Topics: Czechoslovakia; Ethambutol; Humans; Oxazoles; Phenylthiourea; Prothionamide; Rifampin; Thiosemicarbazones; Tuberculosis, Pulmonary | 1977 |
[The effect on sublethal terizidon concentration on the mutation rate for streptomycin- and rifampicin resistance in E. coli].
Topics: Cycloserine; Drug Resistance, Microbial; Escherichia coli; Kinetics; L Forms; Microbial Sensitivity Tests; Mutation; Osmotic Fragility; Oxazoles; Rifampin; Schiff Bases; Streptomycin | 1974 |
Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages.
Topics: Acetamides; Animals; Antitubercular Agents; Cell Line; Drug Antagonism; Furans; Isoniazid; Linezolid; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Oxazoles; Oxazolidinones; Rifampin | 2005 |
Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazoles; Rifampin; Structure-Activity Relationship; Tuberculosis | 2006 |
Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacteria; Cell Line; Cell Survival; Drug Design; Drug Resistance, Multiple, Bacterial; Fungi; Humans; Latent Tuberculosis; Microbial Sensitivity Tests; Microsomes; Mutagens; Mycobacterium tuberculosis; Oxazoles; Primary Cell Culture; Rifampin; Structure-Activity Relationship; Thiadiazoles | 2016 |
Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Bone Wires; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Foreign Bodies; Injections, Intraperitoneal; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Organophosphates; Osteomyelitis; Oxazoles; Rats; Rats, Wistar; Rifampin; Staphylococcal Infections; Tibia; Vancomycin | 2016 |
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rifampin; Tuberculosis, Multidrug-Resistant | 2017 |
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
Topics: Antitubercular Agents; Communicable Disease Control; Databases, Factual; Diarylquinolines; Humans; Infectious Disease Medicine; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Patient Safety; Public Health; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Prevention of High-Level Daptomycin-Resistance Emergence In Vitro in Streptococcus mitis-oralis by Using Combination Antimicrobial Strategies.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Daptomycin; Drug Combinations; Drug Resistance, Bacterial; Gentamicins; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Organophosphates; Oxazoles; Rifampin; Streptococcus mitis; Streptococcus oralis; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.
Topics: Adult; Antitubercular Agents; Female; Humans; Logistic Models; Male; Nitroimidazoles; Oxazoles; Retrospective Studies; Rifampin; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.
Topics: Adolescent; Adult; Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Liberation; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Nitroimidazoles; Oxazoles; Proof of Concept Study; Rifampin; Treatment Outcome; Young Adult | 2018 |
Stability of tedizolid phosphate-sodium rifampicin and tedizolid phosphate-meropenem admixtures in intravenous infusion bags stored at different temperatures.
Topics: Anti-Bacterial Agents; Chromatography, Liquid; Drug Stability; Drug Storage; Freezing; Infusions, Intravenous; Meropenem; Organophosphates; Oxazoles; Polypropylenes; Refrigeration; Rifampin; Sodium Chloride; Temperature; Time Factors | 2020 |
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa".
Topics: Humans; Nitroimidazoles; Oxazoles; Retrospective Studies; Rifampin; South Africa; Tuberculosis, Multidrug-Resistant | 2020 |
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Topics: Antitubercular Agents; Clofazimine; Cohort Studies; Diarylquinolines; Electrolytes; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Oxazoles; Prospective Studies; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |
Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Digoxin; Drug Interactions; Gemfibrozil; Healthy Volunteers; Humans; Itraconazole; Midazolam; Oxazoles; Pyridines; Quinazolines; Rifampin; Tolbutamide | 2022 |
Pediatric delamanid treatment for children with rifampicin-resistant TB.
Topics: Antitubercular Agents; Child; Humans; Nitroimidazoles; Oxazoles; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |